Key Documents
Sandra Horning
- Emeritus Faculty, Acad Council, Medicine - Oncology
Contact Information
- Clinical Offices
Lymphoma Clinic 875 Blake Wilbur Dr Clinic C Stanford, CA 94305-5820 Telephone Work (650) 498-6000 Fax (650) 725-9113Blood and Marrow Transplantation 875 Blake Wilbur Dr Clinic E Stanford, CA 94305-5820 Telephone Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal InformationAdministrative Contact Sarah Daadi Administrative Assistant Email sedaadi@stanford.edu Tel Work 650-725-6456Not for medical emergencies or patient use
Clinical Focus
- Burkitt's Lymphoma
- Burkitt's Lymphoma - Hematology
- Burkitt's Lymphoma - Medical Oncology
- Hodgkin's Disease - Blood and Marrow Transplant
- Hodgkin's Disease - Medical Oncology
- Leptommeningeal Disease
- Leptommeningeal Disease - Medical Oncology
- Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma - Blood and Marrow Transplant
- Non-Hodgkin's Lymphoma - Medical Oncology
- Oncology
- Oncology (Cancer)
Administrative Appointments
- President, ASCO , (2005– 2006 )
- President-Elect, ASCO , (2004– 2005 )
Honors and Awards
- Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2000)
Professional Education
- Board Certification: Oncology, American Board of Internal Medicine (1981)
- Stanford University School of Medicine (1980) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (1978)
- University of Rochester Medical Center (1978) NY
- University of Rochester Medical Center (1976) NY
- University of Iowa College of Medicine (1975) IA
Postdoctoral Advisees
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Consulting: Amggen
Research Interests
The objectives of the clinical research program are:
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL).
The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.
Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations
Clinical Trials
- A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL Recruiting
- A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma Recruiting
- Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Recruiting
- Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT) Recruiting
- Phase III CHOP + Rituximab vs CHOP + Iodine-131 Monoclonal Anti-B1 Antibody for New Dx Foll NHL Recruiting
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma Recruiting
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Recruiting
- A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma Recruiting
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Second-Line Treatment of Patients With DLBCL Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma Recruiting
- Clinical Trial of PXD101 in Patients With T-Cell Lymphomas Recruiting
- Ph II, Multicenter, Simon 2-Stage of R788 For Relapsed or Refractory T-Cell Lymphoma Recruiting
- Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
- Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed
- Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma No longer recruiting
- Rituximab in Treating Patients With Hodgkin's Lymphoma No longer recruiting
- Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma No longer recruiting
- Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma No longer recruiting
- Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma No longer recruiting
- Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma No longer recruiting
- Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Terminated
- A Dose and Schedule Finding Trial With AMG 531 for CIT in Adults With Lymphoma Completed
- A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma No longer recruiting
- Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms No longer recruiting
- Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma No longer recruiting
- Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma No longer recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma No longer recruiting
- Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas No longer recruiting
- Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma No longer recruiting
Publications
- Am J Surg Pathol. 2009; (4): 591-8
- Blood. 2009;
- J Clin Oncol. 2009; (24): 3879-80
- J Clin Oncol. 2009; (10): 1607-14
- Hell J Nucl Med. 2008 Sep-Dec; (3): 153-6
- Hematol Oncol Clin North Am. 2008; (2): 201-10, v
- J Clin Oncol. 2008; (28): 4537-8
- Biol Blood Marrow Transplant. 2008; (7): 741-7
- J Clin Oncol. 2007; (25): 3902-7
- Cancer. 2007; (1): 25-30
- J Clin Oncol. 2007; (5): 579-86
- J Clin Oncol. 2007; (1): 43-9
- Leuk Lymphoma. 2007; (3): 521-5
- Biol Blood Marrow Transplant. 2006; (7): 703-11
- J Clin Oncol. 2006; (19): 3121-7
- J Natl Compr Canc Netw. 2006; (3): 241-7
- Leuk Lymphoma. 2006; (6): 998-1005
- J Clin Oncol. 2005; (4): 712-9
- J Clin Oncol. 2005; (21): 4634-42
- Arch Dermatol. 2004; (9): 1140-6
- Curr Hematol Rep. 2004; (4): 227-9
- J Clin Oncol. 2004; (15): 3032-8
- J Clin Oncol. 2004; (8): 1454-9
- Blood. 2004; (3): 777-83
- Blood. 2003; (11): 4285-9
- Semin Oncol. 2003; (6 Suppl 17): 29-34
- Cancer J. 2002 Sep-Oct; (5): 367-8
- Curr Oncol Rep. 2002; (5): 424-33
- Blood Rev. 2002; (2): 111-7
- J Clin Oncol. 2002; (3): 630-7
- Biol Blood Marrow Transplant. 2001; (10): 552-60
- Clin Lymphoma. 2001; (3): 185-7
- Biol Blood Marrow Transplant. 2001; (5): 294-301
- Blood. 2001; (2): 404-9
- Biol Blood Marrow Transplant. 2000; (5A): 555-62
- Biol Blood Marrow Transplant. 2000; (5): 506-12
- Biol Blood Marrow Transplant. 2000; (3A): 352-8
- Biol Blood Marrow Transplant. 2000; (3A): 289-300
- Curr Opin Hematol. 2000; (4): 235-40
- Ann Oncol. 2000; 23-7
- J Clin Oncol. 2000; (5): 972-80
- Hematol Oncol Clin North Am. 1999; (5): 889-918
- Semin Hematol. 1999; (3): 270-81
- J Clin Oncol. 1999; (4): 1244
- Ann Oncol. 1998; S97-101
- New England Journal of Medicine. 1998; (21): 1506–14
- Curr Opin Hematol. 1998; (4): 259-63
- Blood. 1997; (3): 814-22
- Blood. 1997; (3): 801-13
- Ann Oncol. 1997; (6): 601-3
- Hematol Oncol Clin North Am. 1997; (5): 919-35
- Curr Opin Hematol. 1997; (4): 286-90
- J Clin Oncol. 1997; (5): 1736-44
- Ann Oncol. 1996; S21-6
- Ann Oncol. 1996; 105-8
- Biol Blood Marrow Transplant. 1996; (2): 76-85
- Cancer. 1995; (6): 1354-9
- J Clin Oncol. 1995; (5): 1080-8
- Blood. 1995; (11): 3334-41
- J Clin Oncol. 1995; (7): 1726-33
- Curr Opin Hematol. 1995; (4): 262-7
- Blood. 1994; (4): 881-4
- J Clin Oncol. 1994; (7): 1349-57
- Ann Oncol. 1994; 23-7
- J Clin Oncol. 1994; (2): 297-305
- J Clin Oncol. 1994; (12): 2552-8
- Cancer. 1993; (12): 4034-42
- Semin Oncol. 1993; (5 Suppl 5): 75-88
- Blood. 1993; (8): 2031-5
- Int J Radiat Oncol Biol Phys. 1993; (5): 771-6
- Transplantation. 1993; (6): 1425-8
- Leukemia. 1993; (10): 1491-5
- Blood. 1992; (3): 825-30
- Ann Intern Med. 1992; (3): 183-9
- Ann Oncol. 1992; (9): 747-54
- Ann Oncol. 1991; 47-50
- Leukemia. 1991; 53-5
- Ann Intern Med. 1991; (2): 145-6
- J Clin Oncol. 1991; (8): 1426-31
- Hematol Oncol Clin North Am. 1991; (5): 891-900
- Cancer. 1991; (9): 1988-93
- Blood. 1990; (5): 1139-45
- J Clin Oncol. 1990; (6): 963-77
- Clin Transpl. 1990; 157-63
- Blood. 1990; (7): 1293-8
- J Clin Oncol. 1989; (8): 1009-17
- Radiology. 1989; (1 Pt 1): 159-64
- Cancer. 1989; (2): 255-9
- Blood. 1989; (3): 651-61
- Recent Results Cancer Res. 1989; 182-90
- J Clin Oncol. 1989; (9): 1281-7
- J Clin Oncol. 1989; (5): 598-606
- Cancer. 1988; (9): 1844-51
- Ann Intern Med. 1988; (3): 183-9
- Am J Clin Pathol. 1988; (3): 257-61
- Int J Radiat Oncol Biol Phys. 1988; (3): 633-9
- J Clin Oncol. 1988; (12): 1822-31